Ligand Pharmaceuticals (LGND) Other Gross PP&E Adjustments (2016 - 2025)
Historic Other Gross PP&E Adjustments for Ligand Pharmaceuticals (LGND) over the last 15 years, with Q3 2025 value amounting to -$7.6 million.
- Ligand Pharmaceuticals' Other Gross PP&E Adjustments fell 631.55% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.6 million, marking a year-over-year decrease of 631.55%. This contributed to the annual value of $8.9 million for FY2024, which is 3575.26% down from last year.
- Ligand Pharmaceuticals' Other Gross PP&E Adjustments amounted to -$7.6 million in Q3 2025, which was down 631.55% from -$8.0 million recorded in Q2 2025.
- In the past 5 years, Ligand Pharmaceuticals' Other Gross PP&E Adjustments registered a high of $17.9 million during Q4 2022, and its lowest value of -$32.1 million during Q3 2022.
- Moreover, its 5-year median value for Other Gross PP&E Adjustments was -$7.6 million (2025), whereas its average is -$7.3 million.
- The largest annual percentage gain for Ligand Pharmaceuticals' Other Gross PP&E Adjustments in the last 5 years was 29379.26% (2021), contrasted with its biggest fall of 29341.77% (2021).
- Quarter analysis of 5 years shows Ligand Pharmaceuticals' Other Gross PP&E Adjustments stood at $11.0 million in 2021, then soared by 63.51% to $17.9 million in 2022, then decreased by 23.06% to $13.8 million in 2023, then tumbled by 35.75% to $8.9 million in 2024, then crashed by 185.78% to -$7.6 million in 2025.
- Its last three reported values are -$7.6 million in Q3 2025, -$8.0 million for Q2 2025, and -$800000.0 during Q1 2025.